SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today introduced a new SureSelect target enrichment solution that allows Ion Proton users to realize the full power of their next-generation sequencers with the industry's leading human exome and custom DNA target enrichment solutions. SureSelect target enrichment is now available for all major sequencing platforms, enabling researchers to achieve the highest-performance target enrichment results with a variety of sequencers.
'The adoption of desktop sequencers has increased dramatically over the past few years, enabling next-generation sequencing to expand further into clinical research,' said Jacob Thaysen, Agilent's vice president of the Genomic Solutions Division. 'We are happy to provide Ion Proton researchers access to one of the industry's leading target enrichment solutions.'
Already used extensively with high-throughput and desktop sequencers, SureSelect solutions yield high sensitivity and specificity with a fast, easy workflow, generating sequencer-ready samples in only 1.5 days. A number of other distinctive features include highly uniform sequencing coverage, with more than 99 percent SNP concordance rates. SureSelect's flexibility also enables researchers to easily create custom panels specific to their targets of interest with SureDesign, Agilent's user-friendly online design software.
SureSelect Human All Exon V5 is the most widely used human exome kit and is now available for Ion Proton researchers using the SureSelect TE Reagent Kit for Ion Proton. Agilent provides high-performance flexibility and a complete solution for next-generation target enrichment sequencing, including target enrichment reagents, automation, QC and analysis. For more information, click here to visit Agilent's SureSelect Human All Exon Kits website.
About Agilent in Genomics
Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex offers a same-day sample-to-sequencer workflow, and SureSelect can accurately capture whole exomes and whole methylomes in a single reaction. These are just two products arising from Agilent's expertise in synthesizing custom complex mixtures of long oligonucleotides gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide fluorescent in situ hybridization. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanlyzer to measure sample quality, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.